Corpse flower countdown: Stink Floyd nears bloom
The big picture: When? "That's the million-dollar question!" Reiman spokesperson Andrew Gogerty tells Axios.
"We know it's close, but that's all we know."
The intrigue: Corpse flowers, endangered plants originating from Sumatra, are the drama queens of the plant world — taking up to a decade to bloom for the first time and remaining unpredictable.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Wall Street Journal
8 hours ago
- Wall Street Journal
AI Won't Replace Historians
Axios last month published a list of 'The 10 jobs least and most threatened by AI.' No. 2 on the threatened list, between translators and passenger attendants, was 'historians.' The source is a study by researchers at Microsoft on the implications of generative artificial intelligence on the labor force. The study uses data from Copilot, Microsoft's competitor to ChatGPT, to match user requests with relevant career paths. In doing so, it purports to demonstrate the level to which work activities in certain careers are 'covered' by generative AI. To their credit, the researchers are modest about their findings. They note that in the past, efficiency tools have often tended to increase the value of work, not decrease it. Whether generative AI will have a similar effect is too early to tell.
Axios
6 days ago
- Axios
Why baby probiotics are a thing now
Gut health, a popular topic in wellness circles for years, is now the latest frontier in baby products. Why it matters: Most U.S. babies lack key gut bacteria, per new research, fueling a boom in new prebiotic and probiotic products — and fresh parental confusion. The big picture: Unlike adult microbiomes that are already well-established, new research has found that fresh baby guts are quite responsive to probiotics, says Sharon Donovan, a pediatric nutrition expert and professor at University of Illinois Urbana-Champaign. Context: Probiotics are the "good" bacteria, and prebiotics are food for these bacteria. When infants have enough regular prebiotics — which are found naturally in breast milk — that helps the good bacteria thrive. What's happening: About 3 in 4 infants had insufficient levels of a bacteria called Bifidobacteria, putting them at risk of chronic disease like allergies and asthma, according to initial baby gut study findings published in Nature Communications Biology. Even babies born vaginally and breastfed "have compromised gut microbiomes," says Stephanie Culler, study co-author, scientist and CEO of Persephone Biosciences. By the numbers: Researchers analyzed stool samples from more than 400 infant participants. The study is set to run for seven years. Zoom in: More than 9 in 10 infants lacked a specific kind of Bifidobacterium known as B. infantis, which has "superstar powers," because it's the only Bifidobacterium that can consume all of the breast milk prebiotics, Culler tells Axios. It suppresses bad bacteria, and helps the immune system develop properly, she says. Zoom out: The increase in cesarean sections, formula feeding and antibiotic use over generations could be some of the factors eliminating this bacteria in U.S. babies, researchers speculate. The intrigue: Although B. infantis has largely been wiped from the industrialized world, high levels of it have been found in Old Order Mennonite and Amish babies. And as Americans have overall gotten more allergies in recent years, the Amish haven't. State of play: A number of formulas include prebiotics meant to support the growth of Bifidobacteria. Legacy U.S. formula brands Similac and Enfamil offer blends of prebiotics like the kind naturally found in breast milk (HMOs). Newer brands ByHeart and Nara Organics contain an organic lactose-derived prebiotic (GOS). What's next: More probiotic baby products are coming. Brands like BioGaia already sell drops with L. reuteri meant for colicky infants. Others, like Evivo, include B. infantis. Persephone Biosciences — the company behind the major baby microbiome study — will launch a supplement in September that has both B. infantis and prebiotics. Between the lines: Probiotic supplements aren't FDA-regulated like infant formula is — and the FDA raised safety concerns about probiotics after a preterm infant died in 2023. Although the American Academy of Pediatrics (AAP) found probiotics were linked to lower death rates in preemies, it says in a clinical report that there's not enough evidence to recommend routine use. The group warns that they could pose risks to very sick or immunocompromised babies. The AAP tells Axios it is updating its guidance on probiotics, but hasn't said when it will be released.
Axios
10-08-2025
- Axios
RFK Jr.'s vaccine pullback stokes fears of lost medical breakthroughs
Health Secretary Robert F. Kennedy Jr.'s decision to cut federal funding for mRNA vaccine research is the latest in a series of moves that have the potential to crush future medical breakthroughs and accelerate a brain drain. Why it matters: America has historically led the world in scientific innovation — driving economic growth, strengthening national security, and attracting global talent. But scientists, including some who served in Trump's first administration, warn that lead is slipping away. The mRNA divestment "risks stalling progress in some of the most promising areas of modern medicine," Jerome Adams, surgeon general during the first Trump administration and now a professor at Purdue University, told Axios. "Walking away from this technology now would be like pulling funding from antibiotics after penicillin or from computers after the microchip. It's short-sighted and puts us at a disadvantage globally." State of play: Kennedy said last week that HHS's Biomedical Advanced Research and Development Authority would pull nearly $500 million worth of contracts with universities, drug companies and other labs working on new mRNA vaccines. No new mRNA-based projects will be launched as the administration shifts to "safer, broader vaccine platforms," he added. Scientists refute the implication that mRNA vaccines are unsafe. The technology that brought mRNA COVID vaccines in Trump's first term has been in development for decades. Large scientific trials and real-world data have shown that the vaccines are safe and effective — and capable of training the body's immune system to create antibodies to fight a host of afflictions. HHS, when asked for the research on which Kennedy based this decision, sent Axios a link to a citation collection put together by anti-COVID vaccine advocates, including Steven Hatfill, who promoted the use of the antimalarial drug hydroxychloroquine to treat the virus before vaccines were available despite reports of safety issues. Friction point: mRNA technology is what allowed the most common COVID vaccines to be deployed so quickly, and it's essential to responding to new viral pandemic threats, said Cynthia Leifer, a professor of immunology at Cornell University's College of Veterinary Medicine. "When we have a pandemic, we need to act quickly. We don't have time to wait several years or decades to do testing of older platforms the way they were normally done in years past," she said. "The newer technology could allow us to move so much faster to develop and have these vaccines rolled out to protect people when a pandemic is ongoing," Leifer added. Researchers are also studying how mRNA technology could treat or prevent cancer, HIV, and other chronic diseases — and the science so far is promising. Now, they're worried that progress could be lost. "If we stop now, we could delay or even miss the next generation of cures entirely," said Adams, the former surgeon general. Zoom out: Scientists say some of Kennedy's other changes are stifling innovation, too. Kennedy is working to implement massive staff cuts at HHS, reduce funding for research labs' overhead costs and end National Institutes of Health grants for a wide swath of projects. The cuts, along with the broader Trump administration's immigration restrictions, has already started to steer promising international scientific talent away from the country. Kennedy also is reportedly considering overhauling the U.S. Preventive Services Task Force, whose independent experts establish care and coverage guidelines to account for advances in medical treatments and new disease trends. Its past work included recommending beginning mammograms at 40, which has been credited with saving thousands of lives. The other side: HHS denies that its changes will stymie medical advances. "Those concerns are unfounded and not supported with facts," HHS Communications Director Andrew Nixon told Axios. Kennedy's decision to cut BARDA funding for mRNA work won't affect other government uses involving the technology, HHS said. The Centers for Disease Control and Prevention has endorsed mRNA COVID vaccines for most adults. Between the lines: An independent and bipartisan commission warned Congress in April that China has already pulled ahead of the U.S. in key life sciences areas. The U.S. can stay dominant, but it only has a few years to strengthen its position — and it needs to put significant resources into biotechnology resources, the commission's report said. Reality check: It's impossible to know whether breakthroughs actually won't happen as a result of these policy changes, or which advances we could miss out on. "That is a long-term impact that is hard to measure. What cure wasn't found? What question wasn't asked and investigated?" Richard Besser, CEO of the Robert Wood Johnson Foundation, said. mRNA therapy start-ups are also still raising private investment, which could keep research moving.
